Johnson & Johnson (NYSE:JNJ) Shares Bought by Telos Capital Management Inc.

Telos Capital Management Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 28,301 shares of the company’s stock after purchasing an additional 724 shares during the quarter. Johnson & Johnson accounts for about 1.2% of Telos Capital Management Inc.’s investment portfolio, making the stock its 27th largest holding. Telos Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,942,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Thoroughbred Financial Services LLC increased its position in Johnson & Johnson by 14,147.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock worth $401,425,000 after purchasing an additional 3,986,071 shares in the last quarter. Nordea Investment Management AB increased its position in Johnson & Johnson by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock worth $1,217,494,000 after purchasing an additional 1,079,751 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its position in Johnson & Johnson by 152.1% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 1,083,996 shares of the company’s stock worth $122,372,000 after purchasing an additional 654,085 shares in the last quarter. Royal London Asset Management Ltd. increased its position in Johnson & Johnson by 53.2% during the 4th quarter. Royal London Asset Management Ltd. now owns 1,869,313 shares of the company’s stock worth $199,471,000 after purchasing an additional 648,775 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in Johnson & Johnson by 2,178.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 649,040 shares of the company’s stock worth $83,759,000 after purchasing an additional 620,558 shares in the last quarter. 66.82% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently issued reports on the stock. Wells Fargo & Co reissued an “outperform” rating and set a $157.00 target price (up previously from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. Bank of America reissued a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Raymond James dropped their target price on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research report on Wednesday, July 17th. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Thursday, July 18th. Finally, Barclays assumed coverage on shares of Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 target price for the company. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $148.56.

NYSE JNJ traded down $0.62 on Monday, reaching $130.45. The company had a trading volume of 1,789,220 shares, compared to its average volume of 7,695,500. The firm has a market capitalization of $345.92 billion, a price-to-earnings ratio of 15.95, a PEG ratio of 2.22 and a beta of 0.69. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The firm’s 50-day moving average is $136.70. The company has a quick ratio of 1.13, a current ratio of 1.33 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. Johnson & Johnson’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.10 EPS. As a group, analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

In related news, Director Marillyn A. Hewson purchased 3,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was purchased at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the acquisition, the director now directly owns 3,000 shares in the company, valued at $419,040. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Why is the LIBOR significant?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.